Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Return on Sales (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Return on Sales for 13 consecutive years, with 5.42% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 373.0% year-over-year to 5.42%, compared with a TTM value of 7.68% through Dec 2025, down 2600.0%, and an annual FY2025 reading of 7.64%, down 2610.0% over the prior year.
  • Return on Sales was 5.42% for Q4 2025 at Agios Pharmaceuticals, up from 8.03% in the prior quarter.
  • Across five years, Return on Sales topped out at 105.75% in Q3 2024 and bottomed at 22.08% in Q1 2021.
  • Average Return on Sales over 5 years is 3.64%, with a median of 10.27% recorded in 2024.
  • The sharpest move saw Return on Sales soared 11809bps in 2024, then plummeted -11378bps in 2025.
  • Year by year, Return on Sales stood at 12.22% in 2021, then soared by 103bps to 0.4% in 2022, then plummeted by -3550bps to 13.75% in 2023, then skyrocketed by 33bps to 9.15% in 2024, then surged by 41bps to 5.42% in 2025.
  • Business Quant data shows Return on Sales for AGIO at 5.42% in Q4 2025, 8.03% in Q3 2025, and 9.04% in Q2 2025.